SGS, a global testing, inspection, and certification company, has gained ISO 17025 accreditation to offer extractables and leachables (E&L) testing through its Mississauga lab. This facility specializes in biologics, chemistry and microbiological testing to pharmaceutical, biopharmaceutical, and medical device manufacturers across North America.
ISO 17025 is an internationally recognized benchmark that demonstrates lab competence when it comes to quality management, documentation, and equipment management.
The availability of this service in Canada will increase SGS’s E&L testing capacity for North American clients. SGS’s U.S.-based lab in Fairfield, NJ also offers E&L testing services.
“The demand for extractables and leachables testing is on the rise to validate drug safety in both new drug discovery and novel drug development processes,” said Joseph Bower, Head of Health Science for SGS in North America. “We are pleased to achieve ISO 17025 accreditation of our Mississauga Center of Excellence since it reflects the high standards we uphold in our laboratory operations and reinforces our position as a trusted service provider to the pharma industry.”
SGS’s Mississauga lab provides contract testing services for the pharmaceutical, biopharmaceutical, and medical device segments. Although many SGS labs in North America and worldwide are ISO 17025 accredited, together with E&L testing services, this accreditation strengthens the quality-control at every level. The facility is Health Canada and FDA registered, as well as GMP certified. It also carries the ISO 9001:2015 and ISO 13485:2016 (design and manufacture of medical devices) accreditations.
